CSF2 and neoplasm: The advantage of the intratumoral administration of TMZ using a micro-osmotic pump in GL261 models was previously observed in combination with immunotherapy using granulocyte-macrophage colony-stimulating factor (GM-CSF), and this effect was based on the ability to trigger an immunogenic tumor cell death and, consequently, to favor an increased infiltration of effector cells into the tumor ME (9).